August 9, 2005 CEO/Pres

Richard Gabriel

Listen: Windows Media | Real Media

Read:  Interview Transcript

During the interview, Mr. Gabriel noted that the Company is focused on the development of products for the consumer, forensics and pharmaceutical markets. ``We are targeting a number of areas of expansion that include acquisitions, mergers and licensing technologies,'' he stated.

An audiocast of the interview is available on the Company's website at http://www.dnaprint.com. It also can be accessed at http://www.macreport.net by typing the Company's stock trading symbol in the ``search interviews'' section.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a ``Super EPO'' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(tm) RETINOME(tm), ANCESTRYbyDNA(tm), EURO-DNA(tm).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.